Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery
Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight...
Gespeichert in:
| Veröffentlicht in: | Updates in surgery 2024-10, Vol.76 (6), p.2277-2283 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2283 |
|---|---|
| container_issue | 6 |
| container_start_page | 2277 |
| container_title | Updates in surgery |
| container_volume | 76 |
| creator | Muñoz, Martha Patricia Sánchez Blandón, José Daniel Reyes Gutierrez, Ileana Susana Camba Mendoza, Carlos Manuel Moreno Aguiñaga, Ma. Soledad Aldana Orozco, César Alberto Ortiz |
| description | Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight loss. We performed a single-center, quasi-experimental prospective study. Eligible participants were adults in preoperative management for bariatric-metabolic surgery with body-mass index ≥ 48 kg/m
2
. All patients were assigned liraglutide treatment, with an initial dose of 0.6 mg subcutaneous per day, the dose was increased each week until reaching 3.0 mg for 12 weeks. Weight loss and body composition were evaluated monthly using bioelectric impedance (BIA) (InBody 770 Scale®). We analyzed data using descriptive statistics, central tendency measures and dispersion for quantitative variables and absolute and relative frequencies for qualitative variables. A total of 37 individuals were included in this study, 28 (76%) were female and 9 (24%) were males, with an average age of 44 years. About the BMI, 19 patients (51%) had a BMI > 50 kg/m
2
, 10 (27%) > 40 kg/m
2
and 8 (22%) > 60 kg/m
2
; with a total average BMI of 56.04 kg/m
2
. The initial weight was 147.4 ± 14.9 kg which decreased to 139.3 ± 16.8 kg; after 3 months of liraglutide administration. A total of 35 patients had some degree of weight loss (94.6%), while 2 (5.40%) had no weight changes. The total weight loss was 5.50% at 3 months of liraglutide treatment. Liraglutide could be an effective adjuvant therapy for preoperative weight loss in patients living with severe obesity. |
| doi_str_mv | 10.1007/s13304-024-01828-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3033006928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3033006928</sourcerecordid><originalsourceid>FETCH-LOGICAL-c298t-3e22cc9229fd10ad6f196e5c2000602fbfd3b5285b9c89208b029d35bfe2e9633</originalsourceid><addsrcrecordid>eNp9kEFv3CAQhVHVqonS_IEeKo69uIFh7YVjFDVppZVySaTeEODBIfIaB3CiPeS_h-1ucywSDJp586T3EfKVsx-csfVF5kKwVcOgXi5BNuwDOQUmZCMEh4_HPxf8zwk5z_mR1SPU_v1MToRs12K1Wp-S101IZhiXEnqk6D26Ep5xwpxpmOicMM6YzL5HXzAMD6UZY535mOhc2ziVTF9CeaAZnzEhjRZzKDu6TD2mIYZpoNakYEoKrtliMTaOwdG8pAHT7gv55M2Y8fxYz8j99c-7q1_N5vbm99XlpnGgZGkEAjinAJTvOTN957nqsHVQ03QMvPW9sC3I1ionFTBpGahetNYjoOqEOCPfD75zik8L5qK3ITscRzNhXLIWrMJknQJZpXCQulSDJvR6TmFr0k5zpvfk9YG8ruT1X_Ka1aVvR__FbrF_X_nHuQrEQZDraKrR9WNc0lQz_8_2DbmHkYs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3033006928</pqid></control><display><type>article</type><title>Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Muñoz, Martha Patricia Sánchez ; Blandón, José Daniel Reyes ; Gutierrez, Ileana Susana Camba ; Mendoza, Carlos Manuel Moreno ; Aguiñaga, Ma. Soledad Aldana ; Orozco, César Alberto Ortiz</creator><creatorcontrib>Muñoz, Martha Patricia Sánchez ; Blandón, José Daniel Reyes ; Gutierrez, Ileana Susana Camba ; Mendoza, Carlos Manuel Moreno ; Aguiñaga, Ma. Soledad Aldana ; Orozco, César Alberto Ortiz</creatorcontrib><description>Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight loss. We performed a single-center, quasi-experimental prospective study. Eligible participants were adults in preoperative management for bariatric-metabolic surgery with body-mass index ≥ 48 kg/m
2
. All patients were assigned liraglutide treatment, with an initial dose of 0.6 mg subcutaneous per day, the dose was increased each week until reaching 3.0 mg for 12 weeks. Weight loss and body composition were evaluated monthly using bioelectric impedance (BIA) (InBody 770 Scale®). We analyzed data using descriptive statistics, central tendency measures and dispersion for quantitative variables and absolute and relative frequencies for qualitative variables. A total of 37 individuals were included in this study, 28 (76%) were female and 9 (24%) were males, with an average age of 44 years. About the BMI, 19 patients (51%) had a BMI > 50 kg/m
2
, 10 (27%) > 40 kg/m
2
and 8 (22%) > 60 kg/m
2
; with a total average BMI of 56.04 kg/m
2
. The initial weight was 147.4 ± 14.9 kg which decreased to 139.3 ± 16.8 kg; after 3 months of liraglutide administration. A total of 35 patients had some degree of weight loss (94.6%), while 2 (5.40%) had no weight changes. The total weight loss was 5.50% at 3 months of liraglutide treatment. Liraglutide could be an effective adjuvant therapy for preoperative weight loss in patients living with severe obesity.</description><identifier>ISSN: 2038-131X</identifier><identifier>ISSN: 2038-3312</identifier><identifier>EISSN: 2038-3312</identifier><identifier>DOI: 10.1007/s13304-024-01828-0</identifier><identifier>PMID: 38573447</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Bariatric Surgery - methods ; Body Composition ; Body Mass Index ; Female ; Humans ; Liraglutide - administration & dosage ; Liraglutide - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Obesity, Morbid - complications ; Obesity, Morbid - surgery ; Original Article ; Preoperative Care - methods ; Preoperative Period ; Prospective Studies ; Surgery ; Treatment Outcome ; Weight Loss</subject><ispartof>Updates in surgery, 2024-10, Vol.76 (6), p.2277-2283</ispartof><rights>Italian Society of Surgery (SIC) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Italian Society of Surgery (SIC).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c298t-3e22cc9229fd10ad6f196e5c2000602fbfd3b5285b9c89208b029d35bfe2e9633</cites><orcidid>0000-0003-1428-0616</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13304-024-01828-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13304-024-01828-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38573447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Muñoz, Martha Patricia Sánchez</creatorcontrib><creatorcontrib>Blandón, José Daniel Reyes</creatorcontrib><creatorcontrib>Gutierrez, Ileana Susana Camba</creatorcontrib><creatorcontrib>Mendoza, Carlos Manuel Moreno</creatorcontrib><creatorcontrib>Aguiñaga, Ma. Soledad Aldana</creatorcontrib><creatorcontrib>Orozco, César Alberto Ortiz</creatorcontrib><title>Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery</title><title>Updates in surgery</title><addtitle>Updates Surg</addtitle><addtitle>Updates Surg</addtitle><description>Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight loss. We performed a single-center, quasi-experimental prospective study. Eligible participants were adults in preoperative management for bariatric-metabolic surgery with body-mass index ≥ 48 kg/m
2
. All patients were assigned liraglutide treatment, with an initial dose of 0.6 mg subcutaneous per day, the dose was increased each week until reaching 3.0 mg for 12 weeks. Weight loss and body composition were evaluated monthly using bioelectric impedance (BIA) (InBody 770 Scale®). We analyzed data using descriptive statistics, central tendency measures and dispersion for quantitative variables and absolute and relative frequencies for qualitative variables. A total of 37 individuals were included in this study, 28 (76%) were female and 9 (24%) were males, with an average age of 44 years. About the BMI, 19 patients (51%) had a BMI > 50 kg/m
2
, 10 (27%) > 40 kg/m
2
and 8 (22%) > 60 kg/m
2
; with a total average BMI of 56.04 kg/m
2
. The initial weight was 147.4 ± 14.9 kg which decreased to 139.3 ± 16.8 kg; after 3 months of liraglutide administration. A total of 35 patients had some degree of weight loss (94.6%), while 2 (5.40%) had no weight changes. The total weight loss was 5.50% at 3 months of liraglutide treatment. Liraglutide could be an effective adjuvant therapy for preoperative weight loss in patients living with severe obesity.</description><subject>Adult</subject><subject>Bariatric Surgery - methods</subject><subject>Body Composition</subject><subject>Body Mass Index</subject><subject>Female</subject><subject>Humans</subject><subject>Liraglutide - administration & dosage</subject><subject>Liraglutide - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Obesity, Morbid - complications</subject><subject>Obesity, Morbid - surgery</subject><subject>Original Article</subject><subject>Preoperative Care - methods</subject><subject>Preoperative Period</subject><subject>Prospective Studies</subject><subject>Surgery</subject><subject>Treatment Outcome</subject><subject>Weight Loss</subject><issn>2038-131X</issn><issn>2038-3312</issn><issn>2038-3312</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFv3CAQhVHVqonS_IEeKo69uIFh7YVjFDVppZVySaTeEODBIfIaB3CiPeS_h-1ucywSDJp586T3EfKVsx-csfVF5kKwVcOgXi5BNuwDOQUmZCMEh4_HPxf8zwk5z_mR1SPU_v1MToRs12K1Wp-S101IZhiXEnqk6D26Ep5xwpxpmOicMM6YzL5HXzAMD6UZY535mOhc2ziVTF9CeaAZnzEhjRZzKDu6TD2mIYZpoNakYEoKrtliMTaOwdG8pAHT7gv55M2Y8fxYz8j99c-7q1_N5vbm99XlpnGgZGkEAjinAJTvOTN957nqsHVQ03QMvPW9sC3I1ionFTBpGahetNYjoOqEOCPfD75zik8L5qK3ITscRzNhXLIWrMJknQJZpXCQulSDJvR6TmFr0k5zpvfk9YG8ruT1X_Ka1aVvR__FbrF_X_nHuQrEQZDraKrR9WNc0lQz_8_2DbmHkYs</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Muñoz, Martha Patricia Sánchez</creator><creator>Blandón, José Daniel Reyes</creator><creator>Gutierrez, Ileana Susana Camba</creator><creator>Mendoza, Carlos Manuel Moreno</creator><creator>Aguiñaga, Ma. Soledad Aldana</creator><creator>Orozco, César Alberto Ortiz</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1428-0616</orcidid></search><sort><creationdate>20241001</creationdate><title>Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery</title><author>Muñoz, Martha Patricia Sánchez ; Blandón, José Daniel Reyes ; Gutierrez, Ileana Susana Camba ; Mendoza, Carlos Manuel Moreno ; Aguiñaga, Ma. Soledad Aldana ; Orozco, César Alberto Ortiz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c298t-3e22cc9229fd10ad6f196e5c2000602fbfd3b5285b9c89208b029d35bfe2e9633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Bariatric Surgery - methods</topic><topic>Body Composition</topic><topic>Body Mass Index</topic><topic>Female</topic><topic>Humans</topic><topic>Liraglutide - administration & dosage</topic><topic>Liraglutide - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Obesity, Morbid - complications</topic><topic>Obesity, Morbid - surgery</topic><topic>Original Article</topic><topic>Preoperative Care - methods</topic><topic>Preoperative Period</topic><topic>Prospective Studies</topic><topic>Surgery</topic><topic>Treatment Outcome</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muñoz, Martha Patricia Sánchez</creatorcontrib><creatorcontrib>Blandón, José Daniel Reyes</creatorcontrib><creatorcontrib>Gutierrez, Ileana Susana Camba</creatorcontrib><creatorcontrib>Mendoza, Carlos Manuel Moreno</creatorcontrib><creatorcontrib>Aguiñaga, Ma. Soledad Aldana</creatorcontrib><creatorcontrib>Orozco, César Alberto Ortiz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Updates in surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muñoz, Martha Patricia Sánchez</au><au>Blandón, José Daniel Reyes</au><au>Gutierrez, Ileana Susana Camba</au><au>Mendoza, Carlos Manuel Moreno</au><au>Aguiñaga, Ma. Soledad Aldana</au><au>Orozco, César Alberto Ortiz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery</atitle><jtitle>Updates in surgery</jtitle><stitle>Updates Surg</stitle><addtitle>Updates Surg</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>76</volume><issue>6</issue><spage>2277</spage><epage>2283</epage><pages>2277-2283</pages><issn>2038-131X</issn><issn>2038-3312</issn><eissn>2038-3312</eissn><abstract>Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight loss. We performed a single-center, quasi-experimental prospective study. Eligible participants were adults in preoperative management for bariatric-metabolic surgery with body-mass index ≥ 48 kg/m
2
. All patients were assigned liraglutide treatment, with an initial dose of 0.6 mg subcutaneous per day, the dose was increased each week until reaching 3.0 mg for 12 weeks. Weight loss and body composition were evaluated monthly using bioelectric impedance (BIA) (InBody 770 Scale®). We analyzed data using descriptive statistics, central tendency measures and dispersion for quantitative variables and absolute and relative frequencies for qualitative variables. A total of 37 individuals were included in this study, 28 (76%) were female and 9 (24%) were males, with an average age of 44 years. About the BMI, 19 patients (51%) had a BMI > 50 kg/m
2
, 10 (27%) > 40 kg/m
2
and 8 (22%) > 60 kg/m
2
; with a total average BMI of 56.04 kg/m
2
. The initial weight was 147.4 ± 14.9 kg which decreased to 139.3 ± 16.8 kg; after 3 months of liraglutide administration. A total of 35 patients had some degree of weight loss (94.6%), while 2 (5.40%) had no weight changes. The total weight loss was 5.50% at 3 months of liraglutide treatment. Liraglutide could be an effective adjuvant therapy for preoperative weight loss in patients living with severe obesity.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38573447</pmid><doi>10.1007/s13304-024-01828-0</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-1428-0616</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2038-131X |
| ispartof | Updates in surgery, 2024-10, Vol.76 (6), p.2277-2283 |
| issn | 2038-131X 2038-3312 2038-3312 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3033006928 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Bariatric Surgery - methods Body Composition Body Mass Index Female Humans Liraglutide - administration & dosage Liraglutide - therapeutic use Male Medicine Medicine & Public Health Middle Aged Obesity, Morbid - complications Obesity, Morbid - surgery Original Article Preoperative Care - methods Preoperative Period Prospective Studies Surgery Treatment Outcome Weight Loss |
| title | Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A17%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liraglutide%20effectiveness%20in%20preoperative%20weight-loss%20for%20patients%20with%20severe%20obesity%20undergoing%20bariatric-metabolic%20surgery&rft.jtitle=Updates%20in%20surgery&rft.au=Mu%C3%B1oz,%20Martha%20Patricia%20S%C3%A1nchez&rft.date=2024-10-01&rft.volume=76&rft.issue=6&rft.spage=2277&rft.epage=2283&rft.pages=2277-2283&rft.issn=2038-131X&rft.eissn=2038-3312&rft_id=info:doi/10.1007/s13304-024-01828-0&rft_dat=%3Cproquest_cross%3E3033006928%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3033006928&rft_id=info:pmid/38573447&rfr_iscdi=true |